A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2018
At a glance
- Drugs U3 1402 (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 17 Nov 2017 Planned End Date changed from 16 Oct 2017 to 28 Feb 2020.
- 17 Nov 2017 Planned primary completion date changed from 16 Oct 2017 to 28 Feb 2020.
- 17 Nov 2017 Status changed from not yet recruiting to recruiting.